泰林生物 (300813.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	342.7M	339.5M	349.0M	269.9M	373.9M
Cost of Revenue	186.1M	185.2M	197.1M	141.5M	177.3M
Gross Profit	156.6M	154.3M	151.9M	128.4M	196.6M
Operating Expenses
R&D Expense	56.3M	57.2M	62.3M	58.4M	64.5M
SG&A Expense	—	—	—	—	—
General & Admin Expense	40.0M	39.3M	35.3M	31.8M	33.1M
Selling & Marketing Expense	48.3M	46.9M	43.1M	39.2M	42.9M
Other Expenses	—	—	—	—	—
Total Operating Expenses	147.3M	144.4M	151.0M	122.5M	134.9M
Cost and Expenses	333.4M	329.6M	348.2M	264.0M	312.1M
Operating Income (EBIT)	18.3M	16.9M	12.4M	21.8M	79.6M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	18.5M	16.7M	12.8M	22.0M	79.9M
Income Tax Expense	703.9K	452.6K	512.9K	3.5M	261.1K
Bottom Line
Net Income	17.8M	16.5M	13.1M	19.7M	79.7M
Earnings from Cont. Ops	17.8M	16.3M	12.3M	18.4M	79.7M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	17.8M	16.5M	13.1M	19.7M	79.7M
Per Share
Basic EPS	CN¥0.15	CN¥0.14	CN¥0.12	CN¥0.18	CN¥0.74
Diluted EPS	CN¥0.15	CN¥0.14	CN¥0.12	CN¥0.17	CN¥0.71
Revenue Per Share	CN¥2.83	CN¥2.88	CN¥3.21	CN¥2.47	CN¥3.47
Shares
Basic Shares Outstanding	121.0M	117.8M	108.8M	109.3M	107.7M
Diluted Shares Outstanding	121.0M	117.8M	108.8M	109.3M	107.7M
Profitability Metrics
EBITDA	—	37.8M	33.1M	36.2M	91.7M
D&A	—	20.8M	20.7M	14.4M	12.1M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026